NKTR
SHORT CANDIDATEMeanRevComposite
29.50
Technical
76.40
Fundamental
13.80
Rank
—
Price
75.92
Hurst
0.13
As of
Aug 14, 2026
Daily
Nektar Therapeutics
HealthcareBiotechnologyNektar Therapeutics is a biopharmaceutical company developing immunotherapy treatments for autoimmune, inflammatory, and oncological conditions. The company's pipeline includes multiple drug candidates targeting conditions such as ulcerative colitis, vitiligo, multiple sclerosis, fibrotic diseases, and various cancers. It maintains research partnerships with several major pharmaceutical firms including Takeda, AstraZeneca, Roche, Pfizer, and Bristol-Myers Squibb.
Market cap
$2.3B
P/E (trailing)
—
P/E (forward)
-6.30
PEG ratio
0.31
Dividend yield
—
Beta
1.15
52w range
33.40 – 109.00
Return on equity
-35.76%
Profit margin
-287.84%
Revenue growth
-9.30%
Earnings growth
—
Price history
1Y: 68.36 (+16.3%) · range 35.12–100.35
Cycle position
41/ 100 cycle scoreAPPROACHING ENTRY
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 37 · WEAK SETUP · exit proximity 0
Conviction
27/ 100 · maturity 100%
VScore.4016
Buildup.2045
EMA entry setup.2537
Fundamentals.1514
Volume profile
POC
67.85
Price vs POC
+0.8%
Overhead supply
62%
Runway
+0.9%
Value area 58.52–77.18 · 62% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| squeeze-risk | 0.459 | Aug 31, 2026 |
| short-interest | 0.223 | Aug 31, 2026 |
| earnings-surprise | 0.033 | Sep 11, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -4.46% | +4.59% | 19/20d |
| 40d | -4.46% | +4.59% | 19/40d |